ERBB2 and neoplasm: Activation of APCs may increase processing and presentation of endogenous tumor antigens from dying cells, resulting in 'epitope spreading', which refers to the development of immunity to tumor antigens other than HER2/neu and which could halt the progression of HER2/neu-negative variants [55].